Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sunesis

Sunesis
1998 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
SNSS STOCK SYMBOL
$1.47 SHARE PRICE (As of Wednesday Closing)
Description

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Sunesis’s full profile, request a free trial.

Sunesis Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.20 - $2.96 $99M $1.30 -$0.75 959K 67.6M

Sunesis Financials Summary

In Thousands,
USD
TTM
31-Dec-2018
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 23,708 11,976 117,031 53,444
Revenue 237 237 669 2,536
EBITDA (25,452) (25,452) (34,053) (36,291)
Net Income (26,615) (26,615) (35,458) (38,023)
Total Assets 15,324 15,324 34,334 43,234
Total Debt 7,396 7,396 7,204 14,435
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sunesis Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sunesis‘s full profile, request access.

Request full access to PitchBook

Sunesis Competitors (54)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Loxo Oncology Formerly VC-backed Stamford, CT 00 00000 000000&0 00000
000000 00000000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
000000000000 00000 Corporate Backed or Acquired Trevose, PA 000 00000 00000000000 00000
000000 00000000000 Corporate Backed or Acquired San Francisco, CA 000 00.000 000000000 00.000
000000000 00000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
To view this company’s complete list of competitors, request access »

Sunesis Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sunesis‘s full profile, request access.

Request full access to PitchBook

Sunesis Executive Team (15)

Name Title Board
Seat
Contact
Info
Dayton Misfeldt Interim Chief Executive Officer & Board Member
William Quinn Chief Financial Officer & Senior Vice President, Finance and Corporate Development
Judith Fox Ph.D Chief Scientific Officer
Deborah Thomas Ph.D Senior Vice President, Regulatory Affairs, Quality Assurance and Nonclinical Development
Jennifer Smith Ph.D Vice President, Biometrics

6 Former Executives

You’re viewing 5 of 15 executives. Get the full list »

Sunesis Board Members (11)

Name Representing Role Since Contact
Info
David Stump MD Self Board Member 000 0000
Dayton Misfeldt Self Interim Chief Executive Officer & Board Member 000 0000
Geoffrey Parker Self Board Member 000 0000
Homer Pearce Ph.D Self Board Member 000 0000
Matthew Fust Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »